TGTX Rallies As TG Therapeutics Hikes 2026 Revenue Outlook

TG Therapeutics Inc. stocks have been trading up by 9.62 percent amid heightened optimism from its most recent clinical progress news

Weekly Update Aug 17 – Aug 21, 2026: On Sunday, August 23, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 9.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

TG Therapeutics sits in a unique position as a single-asset commercial biotech now transitioning into a high‑margin MS franchise. Revenue of $616M with three‑year CAGR above 220% and gross margin near 93% underscore strong pricing power and payer acceptance for BRIUMVI. Profitability is emerging, with 11% EBIT margin and 55% net margin distorted by non‑cash items, while ROE above 100% reflects an equity‑light, IP‑rich model. Liquidity is ample (current ratio 4.3, ~$483M cash) despite moderate leverage (D/E ~1.25x).

Technically, TGTX is in a clear short‑term uptrend: the weekly strip from ~$49 to a $55.42 close shows steady higher highs and higher lows with a strong breakout day on 8/21. Intraday 5‑minute action indicates aggressive dip‑buying above $51–52 and rising volume into the close, consistent with institutional accumulation. The key actionable level is $52: above it, pullbacks are buyable; a decisive break below $50 would signal failed breakout and justify tight risk management.

Fundamentally and versus biotech benchmarks, TGTX now resembles a profitable specialty pharma rather than a binary‑risk biotech. Street expects ~$950M 2026 revenue and near‑$1B BRIUMVI U.S. run‑rate, far ahead of typical small‑mid cap peers, with incremental upside from subcutaneous BRIUMVI and new indications. Takeover chatter adds optionality but is not central to the thesis. I see fair value at $75–85 over 12–18 months, with support at $50 and resistance in the low $60s near term.

Quick Financial Overview

TG Therapeutics Inc. is showing traders a classic high‑growth, high‑volatility profile. On the income side, Q2 operating revenue of about $240M is driven mainly by BRIUMVI, backed by a gross margin near 92.7%. Profitability metrics are unusual but strong for a mid‑cap biotech, with profit margin above 55% and a trailing P/E near 19.8, which is modest relative to triple‑digit revenue growth of more than 220% over three and five years.

Balance sheet strength underpins the story. Cash and equivalents around $483.9M (and $612M cited in commentary) along with a current ratio of 4.3 give TGTX room to fund trials and commercial expansion. Debt is not trivial, with long‑term borrowings roughly $752.5M and total debt‑to‑equity at 1.25, but interest coverage of 2.5 and strong operating cash flow near $39.3M suggest the capital structure is manageable for now.

Price action confirms both momentum and risk. The weekly chart shows TGTX grinding higher from roughly $49 to over $55 into late August, with a particularly strong push on 2026/08/21 as price closed near $55.42 after trading as high as $55.45. Intraday, a 5‑minute bar that ran from $51.10 to an intraday high of $56.87 before settling near $54.27 highlights the kind of wide intraday ranges traders must respect when sizing positions and setting stops.

Conclusion

TG Therapeutics Inc. sits at the intersection of fast fundamental growth and sharp tape swings, which is exactly where active traders often find opportunity. Revenue is expanding rapidly, BRIUMVI is scaling with 64% U.S. growth, and management has pushed 2026 guidance to about $950M with a $1B U.S. BRIUMVI run‑rate target. At the same time, the stock has shown it can drop more than 10% in a single session around earnings and guidance resets.

Valuation, with a P/E near 19.8 and price‑to‑sales above 10, already bakes in a good chunk of optimism, helped by a Street backdrop of Buy ratings and targets above current prices. For short‑term traders, that means strong catalysts cut both ways: positive Phase 3 data, guidance raises, or confirmed M&A can squeeze the stock higher, while any stumble on BRIUMVI growth or pipeline news can trigger fast downside. This is exactly the type of name where flexibility and responsiveness matter; as millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” Keeping that in mind can help traders frame their approach to such a volatile, catalyst‑driven stock.

For TGTX, the key watch items are BRIUMVI quarterly trends, progress on subcutaneous and new indications, and how the stock behaves around the $50–$55 band that has become a near‑term pivot zone. As I tell my students, “The edge is not in predicting the story, it’s in reading the tape around the story and managing your risk with discipline.” This article is for educational and research purposes only, and traders should do their own work before acting on TG Therapeutics Inc.
“,”scores”:{“risk-level”:”High”},”trade”:”true

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks